CEL-SCI Corp (CVM) Announces Submission of Response to FDA Partial Clinical Hold on Multikine Phase 3

November 21, 2016 8:31 AM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

CEL-SCI Corporation (NYSE: CVM) announced today that it has submitted its response to the U.S. Food and Drug Administration (FDA) regarding the previously announced partial clinical hold of CEL-SCI’s Phase 3 clinical trial of its investigational drug Multikine* (Leukocyte Interleukin, Injection) in patients with squamous cell carcinoma of the head and neck.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News

Add Your Comment